• The Institute of Advanced Study in Science and Technology (IASST), Guwahati, has identified IL-35 as a promising treatment for type 1 and autoimmune diabetes mellitus.

• IL-35 refers to Interleukin-35, a cytokine belonging to the interleukin family.

• This protein, composed of IL-12α and IL-27β chains encoded by the IL12A and EBI3 genes, plays a pivotal role in regulating immune responses.

• By reducing inflammatory immune cells and controlling pancreatic beta cell infiltration, IL-35 helps prevent immune cells from attacking insulin-producing cells.

• The research team employed network pharmacological analysis to examine IL-35-related genes and disease interactions.

• They identified five key genes associated with immune-inflammatory and autoimmune disorders.

• The study, published in CYTOKINE and World Journal of Diabetes, highlights IL-35’s potential to protect the immune system and offers new hope for diabetes management.

• Further research is needed to elucidate IL-35's mechanisms and advance this promising therapy to clinical trials

Click here to read more.